His primary areas of investigation include Lung cancer, Cancer research, Epidermal growth factor receptor, Internal medicine and Adenocarcinoma. His Lung cancer study focuses on T790M in particular. His research in Cancer research intersects with topics in Mutation, Gene, Gene mutation, Exon and Tumor suppressor gene.
His Epidermal growth factor receptor research includes elements of Gene duplication, KRAS and Pharmacology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Surgery and Oncology. His biological study spans a wide range of topics, including Immunohistochemistry, Lymph node, Pathology and Respiratory disease, Lung.
His main research concerns Lung cancer, Internal medicine, Oncology, Cancer research and Epidermal growth factor receptor. His Lung cancer research is multidisciplinary, incorporating elements of Cancer and Adenocarcinoma. His work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine.
Tetsuya Mitsudomi has included themes like Stage, Clinical trial, Cisplatin and Hazard ratio in his Oncology study. In his study, Osimertinib is inextricably linked to T790M, which falls within the broad field of Cancer research. The various areas that Tetsuya Mitsudomi examines in his Epidermal growth factor receptor study include Tyrosine kinase, Molecular biology and Tyrosine-kinase inhibitor.
Tetsuya Mitsudomi mainly focuses on Lung cancer, Internal medicine, Oncology, Cancer research and Osimertinib. The study incorporates disciplines such as Lung and Adenocarcinoma in addition to Lung cancer. His study looks at the intersection of Adenocarcinoma and topics like Pathology with Metastasis.
Within one scientific family, Tetsuya Mitsudomi focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Carcinoembryonic antigen. His Oncology study combines topics from a wide range of disciplines, such as Stage and Chemotherapy. His Cancer research study incorporates themes from Acquired resistance, Epidermal growth factor receptor, Mutation, Afatinib and Exon.
The scientist’s investigation covers issues in Lung cancer, Cancer research, Internal medicine, Osimertinib and T790M. His Lung cancer research integrates issues from Cancer, Adenocarcinoma and Immunology. Tetsuya Mitsudomi interconnects Erlotinib, Epidermal growth factor receptor, Afatinib, Mutation and Pathology in the investigation of issues within Cancer research.
His Internal medicine study frequently draws connections to other fields, such as Oncology. His Oncology research is multidisciplinary, incorporating elements of Chemotherapy and Hazard ratio. His work in Osimertinib addresses subjects such as Epithelial–mesenchymal transition, which are connected to disciplines such as CD44 and Gene knockdown.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
Junichi Takamizawa;Hiroyuki Konishi;Kiyoshi Yanagisawa;Shuta Tomida.
Cancer Research (2004)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro.
Lancet Oncology (2010)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer Biological and Clinical Implications
Takayuki Kosaka;Yasushi Yatabe;Hideki Endoh;Hiroyuki Kuwano.
Cancer Research (2004)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi;Manabu Soda;Yoshihiro Yamashita;Toshihide Ueno.
The New England Journal of Medicine (2010)
Increased Expression of Cyclooxygenase 2 Occurs Frequently in Human Lung Cancers, Specifically in Adenocarcinomas
Toyoaki Hida;Yasushi Yatabe;Hiroyuki Achiwa;Hideki Muramatsu.
Cancer Research (1998)
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
Tetsuya Mitsudomi;Takayuki Kosaka;Hideki Endoh;Yoshitsugu Horio.
Journal of Clinical Oncology (2005)
Reduced expression of Dicer associated with poor prognosis in lung cancer patients.
Yoko Karube;Hisaaki Tanaka;Hisaaki Tanaka;Hirotaka Osada;Shuta Tomida.
Cancer Science (2005)
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
Takayuki Kosaka;Yasushi Yatabe;Hideki Endoh;Kimihide Yoshida.
Clinical Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: